Nedaplatin
Based on 1 publication(s) in Google Scholar
Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 95734-82-0
- Formula: C2H8N2O3Pt
- Molecular Weight:303.18
-
Storage:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-17394
CisplatinDNA Alkylator -
HY-17393
CarboplatinDNA Synthesis Inhibitor -
HY-B0015
PaclitaxelAntitumor Agent -
HY-17371
OxaliplatinDNA Synthesis Inhibitor -
HY-B0011
DocetaxelMicrotubule Depolymerization Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-13629
EtoposideTopoisomerase II Inhibitor -
HY-12163
EntinostatHDAC Class I Inhibitor -
HY-P99974
Nab-PaclitaxelAlbumin-Bound Paclitaxel -
HY-13067
CelastrolAutophagy Inducer -
HY-90006
5-FluorouracilThymidylate Synthase Inhibitor -
HY-B0016
CapecitabineDNA/RNA Synthesis Inhibitor
Publications Citing Use of MedChemExpress (MCE) Nedaplatin
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[1]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 95734-82-0
-
Appearance Solid
-
Molecular Weight 303.18
-
Formula C2H8N2O3Pt
-
Color Light yellow to yellow
-
SMILES
O=C1C[O-][Pt+2](N)(N)[O-]1
-
Synonyms
NSC 375101D
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Vet Parasitol
Inhibiting thioredoxin glutathione reductase is a promising approach to controlling Cryptocaryon irritans infection in fish. [Abstract]2023 Aug:320:109972. PMID: 37385103
Solvent & Solubility
In Vitro:
H2O : 8.33 mg/mL (27.48 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Nedaplatin's activity)
DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin's activity)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 7.14 mg/mL (23.55 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Protocols
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (585 KB)
- English - EN (585 KB)
- Français - FR (585 KB)
- Deutsch - DE (585 KB)
- Norwegian - NO (585 KB)
- Español - ES (585 KB)
- Swedish - SV (585 KB)
- Italian - IT (585 KB)
- Korean - KR (585 KB)
- Portuguese - PT (585 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kanzawa, F., et al., In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res, 2001. 7(1): p. 202-9. [Content Brief]
[2]. Uchida, N., et al., Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer, 1998. 34(11): p. 1796-801. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.2984 mL | 16.4919 mL | 32.9837 mL | 82.4593 mL |
| 5 mM | 0.6597 mL | 3.2984 mL | 6.5967 mL | 16.4919 mL | |
| 10 mM | 0.3298 mL | 1.6492 mL | 3.2984 mL | 8.2459 mL | |
| 15 mM | 0.2199 mL | 1.0995 mL | 2.1989 mL | 5.4973 mL | |
| 20 mM | 0.1649 mL | 0.8246 mL | 1.6492 mL | 4.1230 mL | |
| 25 mM | 0.1319 mL | 0.6597 mL | 1.3193 mL | 3.2984 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Nedaplatin Related Classifications
HY-13700 Related Classifications
Powered by Bioz